Antithrombotic Therapy Does Not Improve Outcomes in Recurrent Miscarriage

 In women with 2 or more unexplained miscarriages, aspirin therapy alone or in combination with the low-molecular-weight heparin derivative nadroparin does not increase the live-birth rate, relative to placebo, despite its widespread use for this purpose.

That is according to the randomized placebo-controlled Anticoagulants for Living Fetuses (ALIFE) study, published online March 24 in the New England Journal of Medicine.